Ora is the world’s leading independent, full-service ophthalmic clinical research and product development firm with offices in the United States and Japan. Over the past 30 years, we helped our clients earn 39 FDA approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently and successfully bring their new products from concept to market. Ora’s pre-clinical and clinical models, unique methodologies and regulatory strategies have been refined and proven across thousands of projects both in the US and internationally. We bring together the world’s most extensive and experienced network of ophthalmic experts and R&D professionals to maximize the value of new product initiatives.
Location: United States, Massachusetts, Andover
Employees: 201-500
Phone: +1 866-393-3767
Founded date: 1977
Investors 1
| Date | Name | Website |
| 07.01.2025 | The Vistri... | vistria.co... |
Mentions in press and media 6
| Date | Title | Description |
| 01.05.2024 | Ora, Inc. to showcase latest technologies and research at ARVO 2024, convene groundbreaking ophthalmic symposium Dry Horizons | Ora booth #1630 at ARVO to highlight Blind Canvas Project, which creates AI-assisted artistic renderings of the lived experiences of the visually impaired BOSTON, May 1, 2024 /PRNewswire/ -- Ora, Inc., the world's leading partner for ophtha... |
| 22.09.2022 | Trials of Tomorrow: The Latest Technologies Advancing Dry Eye Disease Research, Upcoming Webinar Hosted by Xtalks | The COVID-19 pandemic has accelerated innovation in telehealth, hybrid healthcare partnering in-person visits with online tools and new technologies with at-home patient data capture capabilities. TORONTO (PRWEB) September 22, 2022 The quin... |
| 15.08.2022 | Community is The New Network: Developing Clinical Trial Site Relationships in Ophthalmic Research, Upcoming Webinar Hosted by Xtalks | Reinventing the typical site network to become a more closely collaborative, integrated community will benefit investigators, patients, and ophthalmic innovators. TORONTO (PRWEB) August 15, 2022 While many of the foundational elements have ... |
| 12.05.2022 | Ora Leadership to be Featured in Upcoming Retinal Research Webinar hosted by Xtalks | TORONTO (PRWEB) May 12, 2022 Keith Lane, Vice President, Ora Posterior Segment; and Dr. Sally Tucker, Vice President, Ora Europe, will share insights and strategies for improving clinical study success, navigating development program hurdle... |
| 26.02.2021 | Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease | LUXEMBOURG (PRWEB) February 26, 2021 Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company, and Essex Bio-Technology, a China-based bio-pharmaceutical company, announced positive data from their VISTA-2 study (NCT04206020) –... |
| 12.12.2019 | electrifying vision: announcing our investment in 2c tech | ExSight Ventures (“EV”) joined a $10 million Series B financing round in 2C Tech Corporation Inc. (the “Company” or “2C Tech”), an early-stage biotechnology company. 2C Tech is developing nanoparticle technology to treat a number of retinal... |